Q2 2026 saw modest organic sales growth and resilient profitability, driven by strong Health & Medical and Professional Hygiene segments. Cost savings and innovation supported margins, while integration of the Feminine Care acquisition and strategic reviews continue.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.